Figure 5.

Spatial information scores, in-field firing rates, proportion of in-field firing, and mean resultant length of CA1 and CA2/3 hippocampal place cells in WT and AD rats. Results are shown as age-adjusted mean scores across neurons in the control (vehicle only), 10 mg/kg, and 30 mg/kg M₁ mAChR agonist VU0364572 conditions. A. Spatial information scores. Place cells of AD rats showed reduced spatial information scores relative to those of WT rats, particularly in the CA2/3 region across all drug conditions (region by genotype interaction, p <0.001; see Results). B. In-field firing rates. Relative to the control condition, oral administration of VU0364572 decreased in-field firing rates of AD hippocampal place cells yet increased in-field firing rates of WT hippocampal place cells (drug condition by genotype interaction, p <0.05; see Results). C. Proportion of in-field firing. Place cells of AD rats showed lower proportions of in-field firing relative to those of WT rats, particularly in the CA2/3 region across all drug conditions (region by genotype interaction, p <0.001; see Results). D. Mean resultant length of spikes relative to phase of theta oscillations. Administration of VU0364572 influenced the magnitude of theta phase modulation of spiking differently for AD and WT rats (drug condition by genotype interaction, p<0.05; see Results). In each panel, error bars show ± SEM. As an additional way of viewing the results, Supplementary Figure 1 replots the data from AD rats in panels A–D as a normalized (Z scored) difference from WT data within each drug condition.